Want to see CLDI full AI Analyst Report?
Calidi Biotherapeutics (CLDI) Income Statement
Calidi Biotherapeutics Income Statement
Last quarter (Q2 2026), Calidi Biotherapeutics's total revenue was $0.00. In Q2, Calidi Biotherapeutics's net income was $-4.16M. See Calidi Biotherapeutics’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Mar 25 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 0.00 | $ 0.00 | $ 0.00 | $ 45.00K | $ 449.00K | |
| $ -1.65M | $ 0.00 | $ -1.26M | $ -229.00K | $ 355.00K | |
| $ 18.59M | $ 21.78M | $ 27.74M | $ 22.90M | $ 10.84M | |
| Depreciation and Amortization | $ 1.65M | $ 1.53M | $ 1.26M | $ 253.00K | $ 153.00K |
| $ -18.19M | $ -19.73M | $ -24.20M | $ -25.00M | $ -9.45M | |
| $ -20.24M | $ -21.78M | $ -28.99M | $ -23.13M | $ -10.48M | |
| $ 192.00K | $ -419.00K | $ -208.00K | $ -2.29M | $ 13.88M | |
| $ -20.05M | $ -22.20M | $ -29.20M | $ -25.42M | $ 3.40M | |
| $ -19.91M | $ -22.14M | $ -29.22M | $ -25.43M | $ -10.93M | |
| Per Share Metrics | |||||
| Basic EPS | $ -95.20 | $ -571.20 | $ -3321.76 | $ -5740.80 | $ 226.56 |
| Diluted EPS | $ -95.20 | $ -571.20 | $ -3321.76 | $ -5740.80 | $ 226.56 |
| Weighted Average Shares Outstanding | 268.88K | 41.53K | 8.76K | 4.41K | 14.91K |
| Weighted Average Shares Outstanding (Diluted) | 268.88K | 41.53K | 8.76K | 4.41K | 14.91K |
Currency in USD
